Literature DB >> 17619811

Colchicine-induced rhabdomyolysis.

Arie Altman1,2, Martine Szyper-Kravitz1,2, Yehuda Shoenfeld3,4,5.   

Abstract

A case of colchicine-induced rhabdomyolysis is reported. A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine. Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis. Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17619811     DOI： 10.1007/s10067-007-0682-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  13 in total

1.  Myopathy associated with chronic colchicine toxicity.

Authors:  H A KONTOS
Journal:  N Engl J Med       Date:  1962-01-04       Impact factor: 91.245

2.  Colchicine-induced myopathy and neuropathy.

Authors:  D S Younger; S A Mayer; L H Weimer; L M Alderson; A H Seplowitz; R E Lovelace
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

3.  Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout.

Authors:  S L Wallace; J Z Singer; G J Duncan; F M Wigley; R W Kuncl
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

4.  Colchicine neuromyopathy after renal transplantation.

Authors:  E H Rieger; N A Halasz; H E Wahlstrom
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

Review 5.  Current aspects of colchicine therapy -- classical indications and new therapeutic uses.

Authors:  U Lange; C Schumann; K L Schmidt
Journal:  Eur J Med Res       Date:  2001-04-20       Impact factor: 2.175

6.  Colchicine induced rhabdomyolysis.

Authors:  I Chattopadhyay; H G Shetty; P A Routledge; J Jeffery
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

Review 7.  Colchicine myotoxicity: case reports and literature review.

Authors:  Kerry Wilbur; Mark Makowsky
Journal:  Pharmacotherapy       Date:  2004-12       Impact factor: 4.705

8.  Colchicine induced rhabdomyolysis.

Authors:  T M Dawson; G Starkebaum
Journal:  J Rheumatol       Date:  1997-10       Impact factor: 4.666

Review 9.  Colchicine in dermatology.

Authors:  T P Sullivan; L E King; A S Boyd
Journal:  J Am Acad Dermatol       Date:  1998-12       Impact factor: 11.527

10.  Chronic human colchicine neuropathy and myopathy.

Authors:  J E Riggs; S S Schochet; L Gutmann; T W Crosby; A G DiBartolomeo
Journal:  Arch Neurol       Date:  1986-05
View more
  7 in total

Review 1.  Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori.

Authors:  Oren Cohen; Garrett Locketz; Alon Y Hershko; Alexander Gorshtein; Yair Levy
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

Review 2.  Rhabdomyolysis: a review, with emphasis on the pediatric population.

Authors:  Essam F Elsayed; Robert F Reilly
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

3.  Stroke and Stroke-like Episodes in Muscle Disease.

Authors:  Josef Finsterer
Journal:  Open Neurol J       Date:  2012-05-18

4.  Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.

Authors:  Zhijun Xie; Huaxiang Wu; Xiaoqing Jing; Xiuyang Li; Yasong Li; Yongmei Han; Xiangfu Gao; Xiaopo Tang; Jing Sun; Yongshen Fan; Chengping Wen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

Review 6.  Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.

Authors:  Huai Leng Pisaniello; Mark C Fisher; Hamish Farquhar; Ana Beatriz Vargas-Santos; Catherine L Hill; Lisa K Stamp; Angelo L Gaffo
Journal:  Arthritis Res Ther       Date:  2021-04-28       Impact factor: 5.156

7.  Dystrophin is a microtubule-associated protein.

Authors:  Kurt W Prins; Jill L Humston; Amisha Mehta; Victoria Tate; Evelyn Ralston; James M Ervasti
Journal:  J Cell Biol       Date:  2009-08-03       Impact factor: 10.539
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.